Sever, Peter

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 6,138

Genetic studies of body mass index yield new insights for obesity biology

Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature

Genetic Associations and EpidemiologyGenetic Mapping and Diversity in Plants and Animals

Cited by 4,534

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet

Blood Pressure and Hypertension StudiesSodium Intake and Health

Cited by 2,909

Interpretation of the evidence for the efficacy and safety of statin therapy

Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet

Lipoproteins and Cardiovascular HealthAntiplatelet Therapy and Cardiovascular Diseases

Cited by 1,857

Defining the role of common variation in the genomic and biological architecture of adult human height

The Electronic Medical Records and Genomics (eMERGE) Consortium, Wood, A. R., The MIGen Consortium, The PAGE Consortium, Study, T. L. C., Esko, T., Yang, J., Vedantam, S., Pers, T. H., Gustafsson, S., et al. (2014) · Nature Genetics

Genetic Associations and EpidemiologyGenetics and Physical Performance

Cited by 1,853

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension

Rothwell, P. M., Howard, S. C., Dolan, E., O'Brien, E., Dobson, J. E., Dahlöf, B., Sever, P. S., & Poulter, N. R. (2010) · The Lancet

Blood Pressure and Hypertension StudiesCardiovascular Health and Disease Prevention

Cited by 1,784

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Williams, B., MacDonald, T. M., Morant, S., Webb, D. J., Sever, P., McInnes, G., Ford, I., Cruickshank, J. K., Caulfield, M. J., Salsbury, J., et al. (2015) · The Lancet

Blood Pressure and Hypertension StudiesHormonal Regulation and Hypertension

Cited by 1,308

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 984

A saturated map of common genetic variants associated with human height

Yengo, L., Vedantam, S., Marouli, E., Sidorenko, J., Bartell, E., Sakaue, S., Graff, M., Eliasen, A. U., Jiang, Y., Raghavan, S., et al. (2022) · Nature

Genetic Associations and EpidemiologyGenetics and Physical Performance

Cited by 825

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 801

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Bonaca, M. P., Nault, P., Giugliano, R. P., Keech, A. C., Pineda, A. L., Kanevsky, E., Kuder, J., Murphy, S. A., Jukema, J. W., Lewis, B. S., et al. (2018) · Circulation

Lipoproteins and Cardiovascular HealthPeripheral Artery Disease Management

Cited by 766

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

Mega, J. L., Stitziel, N. O., Smith, J. G., Chasman, D. I., Caulfield, M. J., Devlin, J. J., Nordio, F., Hyde, C. L., Cannon, C. P., Sacks, F. M., et al. (2015) · The Lancet

Lipoproteins and Cardiovascular HealthGenetic Associations and Epidemiology

Cited by 704

Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke

Rothwell, P. M., Howard, S. C., Dolan, E., O'Brien, E., Dobson, J. E., Dahlöf, B., Poulter, N. R., & Sever, P. S. (2010) · The Lancet Neurology

Blood Pressure and Hypertension StudiesCardiovascular Health and Disease Prevention

Cited by 690

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes

Sever, P. S., Poulter, N. R., Dahlöf, B., Wedel, H., Collins, R., Beevers, G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · Diabetes Care

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 390

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies

Williams, B., MacDonald, T. M., Morant, S. V., Webb, D. J., Sever, P., McInnes, G. T., Ford, I., Cruickshank, J. K., Caulfield, M. J., Padmanabhan, S., et al. (2018) · The Lancet Diabetes & Endocrinology

Hormonal Regulation and HypertensionBlood Pressure and Hypertension Studies

Cited by 347

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

Gupta, A., Thompson, D., Whitehouse, A., Collier, T., Dahlof, B., Poulter, N., Collins, R., & Sever, P. (2017) · The Lancet

Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug Reactions

Cited by 343

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Poulter, N. R., Wedel, H., Dahlöf, B., Sever, P. S., Beevers, D. G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., et al. (2005) · The Lancet

Blood Pressure and Hypertension StudiesSodium Intake and Health

Cited by 319

Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials

Gencer, B., Marston, N. A., Im, K., Cannon, C. P., Sever, P., Keech, A., Braunwald, E., Giugliano, R. P., & Sabatine, M. S. (2020) · The Lancet

Lipoproteins and Cardiovascular HealthAntiplatelet Therapy and Cardiovascular Diseases

Cited by 318

Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension

CHARGE-Heart Failure Consortium, Surendran, P., EchoGen Consortium, METASTROKE Consortium, GIANT Consortium, EPIC-InterAct Consortium, Study, L. C., Wellcome Trust Case Control Consortium, Understanding Society Scientific Group, EPIC-CVD Consortium, et al. (2016) · Nature Genetics

Genetic Associations and EpidemiologyBlood Pressure and Hypertension Studies

Cited by 312

Inflammatory and Cholesterol Risk in the FOURIER Trial

Bohula, E. A., Giugliano, R. P., Leiter, L. A., Verma, S., Park, J.-G., Sever, P. S., Lira Pineda, A., Honarpour, N., Wang, H., Murphy, S. A., et al. (2018) · Circulation

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 280

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER

Sabatine, M. S., De Ferrari, G. M., Giugliano, R. P., Huber, K., Lewis, B. S., Ferreira, J., Kuder, J. F., Murphy, S. A., Wiviott, S. D., Kurtz, C. E., et al. (2018) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 255

Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial

Charytan, D. M., Sabatine, M. S., Pedersen, T. R., Im, K., Park, J.-G., Pineda, A. L., Wasserman, S. M., Deedwania, P., Olsson, A. G., Sever, P. S., et al. (2019) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 210

Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment

Howard, J. P., Wood, F. A., Finegold, J. A., Nowbar, A. N., Thompson, D. M., Arnold, A. D., Rajkumar, C. A., Connolly, S., Cegla, J., Stride, C., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthPain Management and Placebo Effect

Cited by 198

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

Sabatine, M. S., Giugliano, R. P., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S. M., Scott, R., Sever, P. S., & Pedersen, T. R. (2016) · American Heart Journal

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 176